Aplastic anemia
Conditions
Interventions
Hetrombopag treatment group:NA
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Eligibility
Sex/Gender
All
Age
No minimum to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients sign informed consent, voluntarily join the study, and have the willingness and ability to cooperate with the data collection in this study; 2. The clinical diagnosis was non-severe aplastic anemia. 3. To receive standard dose of herombopag (15mg);
Exclusion criteria
Exclusion criteria: 1. Secondary aplastic anemia after treatment of malignant tumor; 2. The patient is undergoing or planning to enroll in a clinical intervention study; 3. Other situations deemed unsuitable for inclusion in the study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and degree of hepatic and renal dysfunction in 4 to 6 months after treatment with standard dose of herombopag;Proportion of patients receiving hematologic response within 4-6 months of treatment with standard dose of herombopag; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of hematological remission within 4-6 months of treatment with standard dose of hexapopal.;All patients were observed for any adverse events after treatment with standard dose of hexapopal; | — |
Countries
China
Contacts
Public ContactJun Shi
Institute of Hematology & Blood Diseases Hospital, China
Outcome results
None listed